GlassScriptPhysician profile
Purnima Thakran
NPI 1184706616
$28,275.48
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $831 · 2021: $2,342 · 2022: $8,285 · 2023: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $20.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.55 |
| Education | $20.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $14,541.45 | 2019 | |
| Sk Life Science, INC. | $6,624.82 | 2020-2023 | Xcopri |
| Livanova USA, INC. | $1,396.88 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $740.95 | 2021-2023 | Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $715.20 | 2019-2023 | |
| Ucb, INC. | $675.37 | 2019-2023 | Fintepla, Briviact |
| Supernus Pharmaceuticals, INC. | $642.31 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $313.75 | 2019-2023 | Austedo Xr |
| Eisai INC. | $221.66 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $220.36 | 2019-2021 | |
| Emd Serono, INC. | $210.67 | 2019 | |
| Neurelis, INC. | $206.04 | 2021-2023 | Valtoco |
| Janssen Pharmaceuticals, INC | $197.39 | 2021-2022 | |
| Amgen INC. | $144.79 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $137.69 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $123.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $119.27 | 2021 | |
| Biogen, INC. | $116.40 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.27 | 2022 | |
| Genzyme Corporation | $96.14 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.12 | 2021 | |
| Akcea Therapeutics, INC. | $68.36 | 2020 | |
| Kyowa Kirin, INC. | $65.34 | 2020 | |
| Argenx US, INC. | $62.75 | 2023 | Vyvgart |
| Lundbeck LLC | $60.81 | 2019-2022 | |
| Tanabe Pharma America, INC. | $47.04 | 2021-2023 | |
| Horizon Therapeutics Plc | $44.99 | 2021-2023 | Uplizna |
| Celgene Corporation | $43.99 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $43.61 | 2020-2021 | |
| Genentech USA, INC. | $37.19 | 2019-2022 | |
| Allergan, INC. | $32.08 | 2020 | |
| Amneal Pharmaceuticals LLC | $26.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $24.75 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.20 | 2021 | |
| Banner Life Sciences, LLC | $21.10 | 2022 | |
| Acorda Therapeutics, INC | $20.11 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.03 | 2022 | |
| Sumitomo Pharma America, INC. | $13.37 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purnima Thakran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.